Plain-English translation of NCT05584761 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination approach using azacitidine — a medication approved to treat blood cancers — together with a small number of stem cells from donated umbilical cord blood. The idea is that the medication kills cancer cells, and then the donated stem cells help your immune system recognize and fight any remaining cancer cells while also helping your blood cells recover.
Many patients with advanced blood cancers like yours are too frail or ineligible for standard stem cell transplants, which are very intensive treatments. This new combination approach is designed to be gentler while still giving you the cancer-fighting benefits of donor stem cells, offering a treatment option where none currently exists.
You likely qualify if…
You likely don't qualify if…
You will receive the medication azacitidine by injection once a week for one week, possibly combined with other oral or intravenous medications depending on which treatment arm you're assigned to. Within 24–96 hours after your medication cycle, you'll receive an infusion of donated stem cells from umbilical cord blood. The study will monitor your blood counts and overall health through blood tests and clinic visits over time to see how you respond to this combination treatment.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China